Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 14/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.45 |
| ▸ | CDK4 | P11802 | 3/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944753 | 0.87 | CCNT1 (0.54) | CDK9CCNT1CDK4CCND1CDK2 | |
| SCHEMBL1944749 | 0.87 | CCNT1 (0.54) | CDK9CCNT1CDK4CCND1CDK2 | |
| SCHEMBL12501652 | 0.80 | CDK9 (0.43) | CDK9CCNT1CDK4CCND1CDK2 | |
| SCHEMBL1224704 | 0.77 | CCNT1 (0.56) | CCNT1 | |
| SCHEMBL1947213 | 0.74 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1465512 | 0.74 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1465429 | 0.74 | CCNT1 (0.74) | CCNT1 | |
| SCHEMBL1462840 | 0.74 | CCNT1 (0.57) | CDK9CCNT1 | |
| SCHEMBL1191970 | 0.73 | CCNT1 (0.75) | CCNT1 | |
| SCHEMBL12501693 | 0.73 | CDK9 (0.51) | CDK9CCNT1CDK4CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |